Agenda Item
ASR
Control 23-000931 |
||
MEETING
DATE: |
04/23/24 |
|
legal entity taking action: |
Board
of Supervisors |
|
board of supervisors district(s): |
2,
5 |
|
SUBMITTING Agency/Department: |
Health
Care Agency (Approved) |
|
Department contact person(s): |
Jennifer
Sarin (714) 834-4099 |
|
|
Veronica
Kelley (714) 834-7024 |
|
Subject: Contract for Laboratory Supplies
and Maintenance
ceo CONCUR |
County Counsel Review |
Clerk of the Board |
||||||||
Concur |
Approved
Agreement to Form |
Discussion |
||||||||
|
|
3
Votes Board Majority |
||||||||
|
|
|
||||||||
Budgeted: Yes |
Current Year
Cost: $20,833 |
Annual Cost: FY 2024-25 $125,000 |
||||||||
|
|
|
||||||||
Staffing Impact: |
No |
# of Positions: |
Sole Source: Yes |
|||||||
Current Fiscal Year Revenue: N/A
|
||||||||||
Prior Board Action: 4/26/2016 #14 |
||||||||||
RECOMMENDED
ACTION(S):
1. |
Approve the Contract
with Bio-Rad Laboratories, Inc. for Laboratory Supplies and Maintenance,
effective May 1, 2024, through April 30, 2027, in an amount not to exceed
$375,000, renewable for one additional two-year period. |
2. |
Authorize the
County Procurement Officer or Deputized designee to execute the Contract with
Bio-Rad Laboratories, Inc. referenced in the Recommended Action above. |
SUMMARY:
Approval
of the Contract with Bio-Rad Laboratories, Inc. for Laboratory Supplies and
Maintenance will allow the Orange County Public Health Laboratory to support
delivery of high-quality services to the public.
BACKGROUND
INFORMATION:
The Orange County Public Health
Laboratory (OCPHL) provides specialized laboratory testing for assessing,
investigating, and analyzing infectious diseases of public health concerning
Orange County.
On April 26, 2016, your Honorable
Board of Supervisors (Board) approved the Contract with Bio-Rad Laboratories
(Bio-Rad) to purchase the QX200 Digital Droplet Polymerase Chain Reaction
(ddPCR) system, effective May 1, 2016, in an amount not to exceed $175,00. On
November 17, 2020, Health Care Agency (HCA) executed the Contract with Bio-Rad
under Deputy Purchasing Agent delegated authority to purchase the QX One ddPCR
system, effective November 17, 2020, in an amount not to exceed $288,802.
Scope
of Services
Through the proposed Sole Source
Contract with Bio-Rad, HCA will purchase maintenance for the ddPCR systems,
reagents and supplies to run molecular assays on the ddPCR systems in support
of wastewater surveillance for severe acute respiratory syndrome coronavirus 2
(SARS-COV-2) and microbial source tracking (MST) studies in select Orange
County watersheds. MST is a molecular technique used to determine where the
sources of pollution in the water are coming from. Health risk to swimmers in
those polluted waters can be better managed if the sources of pollution are
determined to be from human or from animal sources. ddPCR has become the method
of choice for doing microbial source tracking on environmental water samples to
determine the sources of pollution.
The proposed Contract is a sole
source contract. Bio-Rad is the only vendor that incorporates the use of
droplets to accurately and reliably quantitate the targets being measured. The
consumables used to run the QX200 and QX One, as well as the servicing of this
equipment, is proprietary and is only available from Bio-Rad. Orange County
Preference Policy is not applicable to this contract award.
Performance
Outcomes
HCA’s molecular workload using the
QX200 and QX One has continued to gradually increase. In 2021, the lab tested
approximately 350 wastewater samples for SARS-CoV-2 and reported 2264 ddPCR
results. In support of MST studies testing for the presence of human sewage in
storm drains and creeks, the lab received close to 200 samples and reported 299
Polymerase Chain Reaction (PCR) results.
Bio-Rad
has been providing consistent and satisfactory service and support with product
delivery and instrument maintenance. Bio-Rad will be evaluated on an ongoing
basis to ensure ongoing instrument performance and responsiveness.
HCA
now requests that the Board authorize the County Procurement Officer or
Deputized designee to execute the Contract with Bio-Rad, as referenced in the
Recommended Actions.
Bio-Rad
performance has been confirmed as at least satisfactory. HCA has verified there
are no concerns that must be addressed with respect to BIO-Rad's
ownership/name, litigation status or conflicts with County interests.
This
Contract does not currently include subcontractors or pass throughs to other
providers. See Attachment B for Contract Summary Form.
This Contract is being brought
before your Honorable Board of Supervisors (Board) less than 30 days prior to
the Contract's start date. Contractor required time to prepare and submit an
updated quote, which delayed the Agenda Staff Report. HCA is requesting
approval to execute the Contract by May 1, 2024, to prevent a lapse in contract
and maintenance coverage.
FINANCIAL
IMPACT:
Appropriations for this Contract are included in
Budget Control 042 FY 2023-24 Budget and will be included in the budgeting
process for future years.
The proposed Contract includes
provisions allowing HCA to terminate the Contract, reduce the level of
services, and/or renegotiate the levels of services provided, as necessary.
This includes a notice that allows HCA adequate time to transition or terminate
services to clients, if necessary.
STAFFING
IMPACT:
N/A
ATTACHMENT(S):
Attachment
A – Contract No. MA-042-24010442 with Bio-Rad Laboratories, Inc. For Laboratory
Supplies and Maintenance
Attachment B – Contract Summary Form